Climb Bio (CLYM)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	146.18 mm	146.18 mm	146.18 mm	146.18 mm	146.18 mm	146.18 mm
Cash burn (monthly)	25.66 mm	(no burn)	3.91 mm	6.35 mm	2.52 mm	915.67 k
Cash used (since last report)	135.80 mm	n/a	20.70 mm	33.63 mm	13.33 mm	4.85 mm
Cash remaining	10.37 mm	n/a	125.47 mm	112.55 mm	132.84 mm	141.33 mm
Runway (months of cash)	0.4	n/a	32.1	17.7	52.8	154.3

Beta Read what these cash burn values mean

Financial data from Climb Bio earnings reports.

Institutional ownership, Q4 2024

CLYM institutional ownership history Ownership history

96.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	82	75	+9.3%
Opened positions	26	32	-18.8%
Closed positions	19	8	+137.5%
Increased positions	28	27	+3.7%
Reduced positions	12	7	+71.4%

13F shares	Current	Prev Q	Change
Total value	99.02 bn	274.47 bn	-63.9%
Total shares	64.72 mm	65.86 mm	-1.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	31.42 mm	$56.55 bn	0.0%
Ai Eti	5.01 mm	$30.11 mm	0.0%
JHG Janus Henderson	3.18 mm	$5.72 bn	-11.7%
Samsara BioCapital	2.61 mm	$4.70 bn	0.0%
Boxer Capital Management	2.60 mm	$4.69 bn	NEW
BlackRock	2.31 mm	$4.15 bn	+23.5%
Intermediate Capital	2.00 mm	$0.00	0.0%
ICG Life Sciences SCSp	2.00 mm	$20.95 mm	0.0%
Vanguard	1.51 mm	$2.71 bn	-1.2%
Deep Track Capital	1.04 mm	$1.87 bn	-52.0%

Largest transactions	Shares	Bought/sold	Change
Boxer Capital Management	2.60 mm	+2.60 mm	NEW
Boxer Capital	0.00	-2.60 mm	EXIT
BML Investment Partners	0.00	-2.18 mm	EXIT
Deep Track Capital	1.04 mm	-1.13 mm	-52.0%
BAC Bank of America	1.03 mm	+1.02 mm	+5851.4%
Affinity Asset Advisors	500.00 k	-1.00 mm	-66.7%
Cantor Fitzgerald, L. P.	650.50 k	+650.50 k	NEW
Driehaus Capital Management	0.00	-612.39 k	EXIT
Point72 Asset Management	0.00	-590.95 k	EXIT
Kynam Capital Management	547.00 k	+547.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLYM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Jan 25	Brennan Aoife	Stock Option Common Stock	Grant	Acquire A	No	No	1.92	1,150,000	2.21 mm	1,150,000
13 Jan 25	Emily Pimblett	Stock Option Common Stock	Grant	Acquire A	No	No	1.92	100,000	192.00 k	100,000
13 Jan 25	Brett Kaplan	Stock Option Common Stock	Grant	Acquire A	No	No	1.92	500,000	960.00 k	500,000
1 Jan 25	Stephen Basil Thomas	Common Stock	Option exercise	Acquire M	No	No	0	50,188	0.00	154,095
1 Jan 25	Stephen Basil Thomas	RSU Common Stock	Option exercise	Dispose M	No	No	0	50,188	0.00	50,187
19 Dec 24	Emily Pimblett	Common Stock	Sell	Dispose S	No	Yes	2.02	1,235	2.49 k	11,329
18 Dec 24	Emily Pimblett	Common Stock	Option exercise	Acquire M	No	No	0	5,000	0.00	12,564
18 Dec 24	Emily Pimblett	RSU Common Stock	Option exercise	Dispose M	No	No	0	5,000	0.00	25,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

15 Jan 25

Climb Bio Entered Technology Transfer And Exclusive License Agreement With Beijing Mabworks Biotech Co.; Climb Obligated To Pay Mabworks $9M Upfront And Up To $30M On Milestones, With Total Up To $832M Upon Achievement Of Certain Milestones For All Licensed Products

10 Jan 25

On January 8, 2025, Climb Bio, Inc. (the "Company") entered into a technology transfer and exclusive license agreement (the "Agreement") with Beijing Mabworks Biotech Co., Ltd. ("Mabworks"), pursuant to which

Climb Bio To Make Upfront Cash Payment Of $9M To Mabworks Plus Certain Additional Payments Upon Achievement Of Specified Milestones

9 Jan 25

As of December 31, 2024, Climb Bio had cash, cash equivalents and short-term marketable securities of approximately $212.9 million.Following its entry into the license agreement, Climb Bio anticipates that its

Press releases

From Benzinga Pro

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

9 Jan 25

Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)

2 Jan 25

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Climb Bio, Inc. (NASDAQ:CLYM) on behalf of the company's shareholders. The investigation seeks to determine